Determination of ranolazine in rat plasma by liquid chromatography-electrospray ionization mass spectrometry

被引:11
作者
Zhong, J [1 ]
Liu, XQ [1 ]
Chen, Y [1 ]
Zhao, XP [1 ]
Wang, YS [1 ]
Wang, GJ [1 ]
机构
[1] China Pharmaceut Univ, Ctr Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
关键词
LC-ESI-MS; pharmacokinetics; ranolazine; rat plasma;
D O I
10.1365/s10337-005-0712-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid and sensitive liquid chromatographic-mass spectrometric (LC-MS) method, with phenoprolamine hydrochloride (DDPH) as internal standard, has been developed and validated for determination of ranolazine in rat plasma. After liquid-liquid extraction the compound was analyzed by HPLC on a C-18 column, with methanol-10 mM ammonium acetate, 76:24 (v/v), as mobile phase, coupled with electrospray ionization mass spectrometry (ESI-MS). The protonated analyte was quantified by selected-ion monitoring (SIM) with a quadrupole mass spectrometer in positive-ion mode. Calibration plots were linear over the concentration range 0.046-12 mu g mL(-1). Inter and intra-day precision (CV%) and accuracy (RE%) for quality-control samples (0.187, 1.5, and 12 mu g mL(-1)) ranged between 2.96 and 13.38% and between -11.23 and 12.67%, respectively. Extraction recovery of RAN from plasma was in the range 82.77-86.54%. The method enables rapid, sensitive, precise, and accurate measurement of the concentration of ranolazine in rat plasma.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 12 条
[1]  
Anderson J R, 2001, Heart Dis, V3, P263
[2]   Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease [J].
Bagger, JP ;
Botker, HE ;
Thomassen, A ;
Nielsen, TT .
CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (03) :479-484
[3]   Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism [J].
Clarke, B ;
Wyatt, KM ;
McCormack, JG .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1996, 28 (02) :341-350
[4]   CARDIOPROTECTIVE EFFECTS OF RANOLAZINE (RS-43285) IN THE ISOLATED-PERFUSED RABBIT HEART [J].
GRALINSKI, MR ;
BLACK, SC ;
KILGORE, KS ;
CHOU, AY ;
MCCORMACK, JG ;
LUCCHESI, BR .
CARDIOVASCULAR RESEARCH, 1994, 28 (08) :1231-1237
[5]   ESTIMATION OF RANOLAZINE AND 11 PHASE-I METABOLITES IN HUMAN PLASMA BY LIQUID-CHROMATOGRAPHY ATMOSPHERIC-PRESSURE CHEMICAL-IONIZATION MASS-SPECTROMETRY WITH SELECTED-ION MONITORING [J].
HERRON, WJ ;
EADIE, J ;
PENMAN, AD .
JOURNAL OF CHROMATOGRAPHY A, 1995, 712 (01) :55-60
[6]  
LOPASCHUK GD, 1993, J PHARMACOL EXP THER, V264, P135
[7]   Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts [J].
McCormack, JG ;
Barr, RL ;
Wolff, AA ;
Lopaschuk, GD .
CIRCULATION, 1996, 93 (01) :135-142
[8]   THE CHARACTERIZATION OF THE METABOLITES OF RANOLAZINE IN MAN BY LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
PENMAN, AD ;
EADIE, J ;
HERRON, WJ ;
REILLY, MA ;
RUSH, WR ;
LIU, Y .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 1995, 9 (14) :1418-1430
[9]   A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents [J].
Pepine, CJ ;
Wolff, AA .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (01) :46-50
[10]   Role of metabolically active drugs in the management of ischemic heart disease [J].
Schofield R.S. ;
Hill J.A. .
American Journal of Cardiovascular Drugs, 2001, 1 (1) :23-35